John Gordon Freund
Known title: DirectorCIK: 0001296771
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
COLL Outlook Supported by ADHD Trends, Low Generic Risk, Oppenheimer. Oppenheimer notes that Collegium Pharmaceutical's outlook is bolstered by strong demand for ADHD treatments and a low risk of generic competition. The firm’s focus on these areas may help sustain revenue growth. The stock is currently trading near its 52‑week low of $21.43, close to a support level that has been tested repeatedly.
Transaction History
| SIBN | ▲ Buy | Grant | 10,957 | $0 | 6/4/2026 | View on chart |
| COLL | ▼ Sell | Open Market | 20 | $681 | 5/18/2026 | View on chart |
| COLL | ▲ Buy | Option Exercise | 8,700 | $143K | 5/15/2026 | View on chart |
| COLL | ▼ Sell | Open Market | 4,127 | $143K | 5/15/2026 | View on chart |
| COLL | ▲ Buy | Grant | 8,741 | $0 | 5/14/2026 | View on chart |
| COLL | ▼ Sell | Open Market | 11,659 | $401K | 8/8/2025 | View on chart |
| SIBN | ▼ Sell | Open Market | 12,132 | $194K | 8/8/2025 | View on chart |
| COLL | ▲ Buy | Option Exercise | 15,000 | $202K | 6/9/2025 | View on chart |
| COLL | ▼ Sell | Open Market | 6,601 | $202K | 6/9/2025 | View on chart |
| SIBN | ▲ Buy | Grant | 8,675 | $0 | 6/5/2025 | View on chart |
| COLL | ▲ Buy | Grant | 9,791 | $0 | 5/15/2025 | View on chart |
| SIBN | ▲ Buy | Grant | 8,791 | $0 | 6/26/2024 | View on chart |
| COLL | ▲ Buy | Grant | 7,693 | $0 | 5/16/2024 | View on chart |
| SIBN | ▼ Sell | Open Market | 30,000 | $616K | 8/9/2023 | View on chart |
| SIBN | ▲ Buy | Grant | 4,866 | $0 | 6/9/2023 | View on chart |
| COLL | ▲ Buy | Grant | 9,792 | $0 | 5/18/2023 | View on chart |
| SIBN | ▲ Buy | Grant | 8,324 | $0 | 6/16/2022 | View on chart |
| COLL | ▲ Buy | Grant | 14,035 | $0 | 5/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Truist Securities raises SI-BONE price target to $25
Truist Securities kept its existing rating on SI‑BONE and lifted its price target to $25. The new target sits near the midpoint of the nine‑analyst consensus range of $20 to $32, and slightly above the current 52‑week high of $21.89. This adjustment suggests the firm sees further upside potential for the company.
Truist Securities raises SI-BONE price target to $25. Truist Securities kept its existing rating on SI‑BONE and lifted its price target to $25. The new target sits near the midpoint of the nine‑analyst consensus range of $20 to $32, and slightly above the current 52‑week high of $21.89. This adjustment suggests the firm sees further upside potential for the company.